The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Francis Joseph Donnelly. For services to Disability Sport and to the community in Northern Ireland. Nilesh Bhasker Dosa. Founder, icanyoucantoo. For services to Social Equality. George David Dowell. Owner, Worthing Football Club. For services to Association Football and to Disability Awareness. Elissa Rebecca Louise Downie. For services to Gymnasts and to the Sport of Gymnastics. Rebecca Lauren Downie. For services to Gymnasts and to the Sport of Gymnastics. Spencer Drury. Lately Councillor, Royal Borough of Greenwich. For Political and Public Service. James Michael Duffy. Lately Child Protection Manager, Lothian and Borders Police and Police Service of Scotland. For services to Children. Giles Duley. Founder, Legacy of War Foundation. For services to Survivors of Conflict. Mary Alexandra Earps. For services to Association Football. Dr. Gillian Mary Eatough. Lately Chief Executive Officer, Learning Community Trust. For services to Education. Captain Thomas David Eccles. Fisheries Officer, Department of Agriculture, Environment and Rural Affairs. For services to Fisheries, Environment and to Maritime Safety. Linda Jacqueline Edmunds. Consultant Nurse, Heart Failure and Cardiac Rehabilitation, Aneurin Bevan University Health Board. For services to Cardiac Rehabilitation and Heart Failure. Professor Anthony David Edwards. Professor of Paediatrics and Neonatal Medicine, King's College London. For services to Health Research. Huw William Edmond Edwards. Founder Member, Monmouth Male Voice Choir. For services to Music and to Charity. Dr. Alice Elizabeth Ellis (Alice Hartley).
== CLIA-waived tests == Under CLIA, tests and test systems that meet risk, error, and complexity requirements are issued a CLIA certificate of waiver. In November 2007, the CLIA waiver provisions were revised by the United States Congress to make it clear that tests approved by the FDA for home use automatically qualify for CLIA waiver, although many waived tests are not done according to designed protocols – more than 50% of such tests are done incorrectly – and result in medical errors, some with fatal consequences.
Carbodiimides such as dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (DIC) are frequently used for amide bond formation. The reaction proceeds via the formation of a highly reactive O-acylisourea. This reactive intermediate is attacked by the peptide N-terminal amine, forming a peptide bond. Formation of the O-acylisourea proceeds fastest in non-polar solvents such as dichloromethane. DIC is particularly useful for SPPS since as a liquid it is easily dispensed, and the urea byproduct is easily washed away. Conversely, the related carbodiimide 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is often used for solution-phase peptide couplings as its urea byproduct can be removed by washing during aqueous work-up.
Sources: en.wikipedia.org
The compound semiconductors InGaN and InGaP are used in light-emitting diodes (LEDs) and laser diodes. Indium is used in photovoltaics as the semiconductor copper indium gallium selenide (CIGS), also called CIGS solar cells, a type of second-generation thin-film solar cell. Indium is used in PNP bipolar junction transistors with germanium: when soldered at low temperature, indium does not stress the germanium.
Hell Heaven pilots a lobster/fiddler crab–themed Kaijuki called Devil Capture (デビルキャプチャー, Debiru Kyapuchā) in an attempt to kidnap Princess Erika and distract the Dekarangers, but is deleted by Deka Blue while Devil Capture is destroyed by the Pat Striker in its Driving Sword formation. Hell Heaven is voiced by Keikō Sakai (酒井 敬幸, Sakai Keikō). Rikomoian Kevakia (リコモ星人ケバキーア, Rikomo Seijin Kebakīa): A digitally-based chameleon-themed being from Planet Rikomo who is capable of traveling through the internet and emerging from computers, but is powerless outside of one. He uses Hell Heaven to distract the Dekarangers while he kidnaps Princess Erika and ransoms her for her family's Wellness Stone. His physical body is deleted by Deka Red and Blue, but he successfully transfers his data into his personal Kaijuki, Devil Capture 2 (デビルキャプチャー2, Debiru Kyapuchā Tsū), and becomes its AI. Nevertheless, he is destroyed by Dekaranger Robo. Kevakia is voiced by Kōji Tobe (戸部 公爾, Tobe Kōji). Anrian Beildon (アンリ星人ベイルドン, Anri Seijin Beirudon): A rhinoceros-themed criminal from Planet Anri who possesses an armored body and is charged with mass-murder on five planets. While working for the scientist Mano Mark, Beildon turns humans into gasoline for a share of his employer's profits and commits bank robberies to help Mark fund his work until the latter is deleted by the Dekarangers via the D-Bazooka. Beildon is voiced by Kenta Miyake (三宅 健太, Miyake Kenta).
In the mid-1980s to 1990s, Singaporeans could also use the locally based videotext service Singapore Teleview to communicate with one another. The phrase Intelligent Island arose in the 1990s in reference to the island nation's early adaptive relationship with the internet. In 2016, there were an estimated 4.7 million internet users in Singapore, representing 82.5% of the population. The Singapore government does not engage in widespread censoring of the internet, but it maintains a list of one hundred websites—mostly pornographic—that it blocks from home internet access as a "symbolic statement of the Singaporean community's stand on harmful and undesirable content on the Internet". Singapore has the world's highest smartphone penetration rates, in surveys by Deloitte and the Google Consumer Barometer—at 89% and 85% of the population respectively in 2014. The overall mobile phone penetration rate is at 148 mobile phone subscribers per 100 people.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.